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Enterococcus faecium recently evolved from a generally avirulent commensal into a multidrug-resistant
health care-associated pathogen causing difficult-to-treat infections, but little is known about the factors
responsible for this change. We previously showed that some E. faecium strains express a cell wall-anchored
collagen adhesin, Acm. Here we analyzed 90 E. faecium isolates (99% acm) and found that the Acm protein
was detected predominantly in clinically derived isolates, while the acm gene was present as a transposon-
interrupted pseudogene in 12 of 47 isolates of nonclinical origin. A highly significant association between
clinical (versus fecal or food) origin and collagen adherence (P < 0.0003) was also demonstrated, and levels
of adherence were highly correlated (r  0.879) with the amount of cell surface Acm detected by whole-cell
enzyme-linked immunosorbent assay and flow cytometry. Thirty-seven of 41 sera from patients with E. faecium
infections showed reactivity with recombinant Acm, while only 4 of 30 community and hospitalized patient
control group sera reacted (P < 0.0003); importantly, antibodies to Acm were present in all 14 E. faecium
endocarditis patient sera. Although pulsed-field gel electrophoresis indicated that multiple strains expressed
collagen adherence, multilocus sequence typing demonstrated that the majority of collagen-adhering isolates,
as well as 16 of 17 endocarditis isolates, are part of the hospital-associated E. faecium genogroup referred to
as clonal complex 17 (CC17), which has emerged globally. Taken together, our findings support the hypothesis
that Acm has contributed to the emergence of E. faecium and CC17 in nosocomial infections.
Enterococcus faecium, generally considered a normal mam-
malian gut commensal, has emerged in the last 2 decades as a
significant nosocomial pathogen (11, 14, 22). In addition to an
increased incidence of E. faecium infections, increased mor-
bidity and mortality due to vancomycin-resistant E. faecium
(VRE) bacteremia have also been reported, particularly
among patients neutropenic from cancer chemotherapy, those
receiving dialysis, and those who have undergone liver or bone
marrow transplantation (6). For example, a recent study (30)
reported VRE intestinal colonization in 40% of 92 neutropenic
patients, of which 34% developed bacteremia with this organ-
ism, with a subsequent mortality rate of 36%, despite treat-
ment with recently available drugs such as linezolid and dap-
tomycin; this is in marked contrast to the decades before VRE
emerged, when E. faecium infections were rarely seen.
Acquisition of resistance to vancomycin preceded by emer-
gence of resistance to ampicillin, impacting the primary ther-
apies of choice for nonresistant strains, has been assumed to be
the major factor responsible for transforming this organism
from its docile, commensal nature into a significant nosocomial
pathogen (14). It has also been postulated that the recent
clinical success of E. faecium exemplified by the hospital-asso-
ciated E. faecium genogroup, also called clonal complex 17
(CC17), which accounts for the majority of clinical isolates
(11), is due at least in part to the acquisition or evolution of
putative virulence-associated traits, such as enterococcal sur-
face protein (Esp) and a hyaluronidase-like gene (hyl) (23).
However, a contribution of these traits to E. faecium patho-
genesis has not been demonstrated, and we found them in only
49% and 28%, respectively, of clinical E. faecium isolates (23).
The recent emergence of resistance to newer antibiotics, in-
cluding quinupristin-dalfopristin, linezolid, and daptomycin, by
VRE strains emphasizes the need for alternative therapeutic
strategies, which might include immunoprophylaxis or immu-
notherapy by targeting in vivo-expressed virulence-associated
surface proteins. Evidence from other gram-positive pathogens
suggests that the adhesin family of proteins may serve as po-
tential candidates for the development of novel immunother-
apies (24). It was recently shown that combination therapy with
vancomycin plus anti-clumping factor A antibodies was more
effective than vancomycin alone in sterilizing rabbit valvular
vegetations in infective endocarditis caused by methicillin-re-
sistant Staphylococcus aureus (29).
Recently, we identified the collagen-binding adhesin Acm as
a primary and, to date, only documented adhesin of E. faecium
(20). Acm has an N-terminal signal peptide, followed by a
collagen binding A domain, a variable number of B repeats,
and a C-terminal region for sorting and anchoring to pepti-
doglycan. Although we demonstrated that the gene encoding
this adhesin (acm) was present in all 32 E. faecium isolates
tested (20), unlike its staphylococcal homologue Cna, which is
present in 38 to 56% of isolates (26), only 55% of 20 infection-
derived clinical isolates and none of the 10 community-derived
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fecal isolates showed collagen adherence. Sequencing of the
acm locus for six non-collagen-adherent E. faecium isolates
identified a pseudogene in five of them (20), and genetic anal-
ysis confirmed that Acm is sufficient to mediate the attachment
of E. faecium strains to collagen (18, 20). In our most recent
study, we identified the minimal and high-affinity binding sub-
segments of Acm and showed that antibodies against these
Acm subsegments inhibited collagen adherence of E. faecium
cells (16).
In the current investigation, we first studied the collagen-
adhering capability of an additional 90 E. faecium isolates,
derived from human infections, community feces, and animals,
and found a highly statistically significant association between
a clinical origin as the source of the isolate and collagen type
I adherence. We next tested for the presence of an uninter-
rupted acm gene and surface expression of Acm to confirm the
involvement of Acm in this collagen adherence by the diverse
collection of isolates. We have also taken advantage of our
collection of sera from patients with E. faecium endocarditis to
look for evidence that Acm is produced during infections, even
if the infecting strain does not produce Acm in vitro under
standard laboratory growth conditions. The molecular epide-
miological analyses of this study, supported by experimental
endocarditis data from the companion paper (19), suggest that
expression of Acm, the mediator of collagen adherence of E.
faecium, is important for successful competition of this species
in the clinical setting.
MATERIALS AND METHODS
Bacterial strains and growth media. Ninety E. faecium strains isolated over 18
years from diverse locations (Argentina, Belgium, China, Spain, Germany, Nor-
way, and several cities in the United States) were included in this study. These
isolates included some from endocarditis specimens (n  11), other clinical
specimens (Other-Clin group) (n  31), community-derived human feces (n 
26), and animals (either meat products or feces of cattle, chickens, turkeys, or
swine) (n  23). The sources of the Other-Clin isolates included blood, bile,
catheters, sputum, urine, and several types of wounds, among others, and several
isolates in this group are representative of epidemic and outbreak strains (1, 3,
8, 10, 13, 28). Six additional endocarditis isolates for which we assessed the
adherence phenotype in our previous study (20) were included for further char-
acterization. An allelic replacement acm deletion mutant, TX6051 (TX0082
acm::cat) (18), was included as a control strain for flow cytometry analysis.
Brain heart infusion (BHI) broth and agar (Difco Laboratories, Detroit, MI)
were used for routine E. faecium growth.
Colony hybridization for species identification and determination of gene
presence. All of the E. faecium isolates, initially identified to the species level by
biochemical tests, were confirmed by high-stringency colony hybridization, using
intragenic efafm and aac(6)-li probes, as previously described (7, 25). The pres-
ence of the acm gene among the 90 isolates of this study was tested by colony
hybridization, using an intragenic acm probe amplified using the AcmF2 and
AcmR1 primers, which were described earlier (20). The presence of esp and hyl
genes, coding for an enterococcal surface protein (Esp; marker for a putative
pathogenicity island) and a putative hyaluronidase (Hyl), presumptively involved
in virulence or epidemicity, were tested by colony hybridization using intragenic
esp and hyl probes as described earlier (23).
Adherence assay. All isolates were tested for adherence to collagen type I
(Sigma Chemical Co., St. Louis, MO) and bovine serum albumin (BSA), using a
previously described assay (20).
Acm-specific polyclonal antibodies. Production of rabbit polyclonal antibodies
against the recombinant Acm A domain (rAcm A) was described elsewhere (20).
Acm A domain-specific antibodies were eluted from rAcm A coupled to cyano-
gen bromide-activated Sepharose 4B according to the manufacturer’s protocol
(Amersham Biosciences, Piscataway, NJ). The antibodies were concentrated by
ultrafiltration with a 10,000-Da-molecular-mass-cutoff filter (Millipore, Bedford,
MA) and dialyzed against phosphate-buffered saline (PBS), and concentrations
were determined by absorption spectroscopy.
Whole-cell ELISA. Surface expression of Acm on E. faecium cells was detected
by a whole-cell enzyme-linked immunosorbent assay (ELISA) using affinity-
purified Acm A domain (binding domain)-specific antibodies, as described ear-
lier (20). Antiserum raised against formalin-killed TX0016 whole cells (21) was
used as a control to confirm that whole cells of all strains were actually bound to
the microtiter plates.
Flow cytometry. For flow cytometry analysis, bacteria were grown in BHI broth
until entry into stationary phase and washed twice with PBS; 100 l of bacteria
adjusted to an optical density at 600 nm (OD600) of 0.2 in PBS was added to an
Eppendorf tube containing 40 l of newborn calf serum (Sigma) and incubated
for 30 min at room temperature. After centrifugation at 10,000 g for 6 min, 100
l of 20-g/ml preimmune or affinity-purified anti-rAcm A specific antibodies in
dilution buffer (PBS containing 20% newborn calf serum and 0.1% BSA) was
added. Incubation was performed at 4°C for 2 h. The bacteria were washed twice
with 400 l of 0.1% BSA in PBS, and 100 l of 1:100 diluted goat anti-rabbit
immunoglobulin G (IgG) conjugated with F(ab)2 fragment-specific R-phyco-
erythrin (Jackson Immunoresearch, West Grove, PA) in dilution buffer was
added and incubated at 4°C for 2 h. After being washed thrice with 400 l of
0.1% BSA in PBS, cells were resuspended in 500 l of 1% paraformaldehyde in
PBS and were analyzed with a Coulter Epics XL AB6064 flow cytometer (Beck-
man Coulter) and System II software.
PCR method for screening IS element interruptions and sequencing. Chro-
mosomal DNAs from E. faecium isolates were prepared as described earlier (33).
PCR and sequencing of the acm locus were performed using previously de-
scribed primers (20). Screening for pseudogenes due to interruption by insertion
elements (IS elements) was performed by PCR with three sets of overlapping
primers, namely, AcmF1-AcmR4, AcmF2-AcmR1, and AcmF3-AcmR3 (20),
that cover the entire acm locus. Randomly chosen PCR products were sequenced
by the Taq BigDye Terminator method (Applied Biosystems, Foster City, CA) to
confirm the predictions and to identify the IS element.
Human sera. From our serum collection, four study groups were selected for
analysis. Sera from 14 patients with E. faecium endocarditis constituted one
group. A second group consisted of 27 serum samples collected from patients
with E. faecium nonendocarditis infections in hospitals in Nebraska, New York,
Delaware, Michigan, New Jersey, Illinois, and Pennsylvania. The third group
consisted of 15 sera that had been obtained for routine chemistry testing from
hospitalized patients, with no knowledge of their diagnosis; these sera were
included as a control group (nonhealthy control sera). The final group consisted
of 15 human sera from healthy volunteers (normal human sera [NHS]); these
sera were included as a healthy control group. Twenty additional NHS, previ-
ously pooled in groups of three to five, were used for the determination of serum
titers, as described below.
Western blotting and Acm antibody titer determination. The cloning of the E.
faecium TX2555 acm gene, coding for all 501 amino acids of the Acm A domain,
and expression and purification of Acm have been described elsewhere (20).
rAcm A protein was electrophoresed in 4 to 12% NuPAGE bis-Tris gels (In-
vitrogen, San Diego, CA) under reducing conditions in 3-[N-morpholino] pro-
panesulfonic acid buffer and transferred to a polyvinylidene difluoride mem-
brane. The presence of anti-Acm antibodies was detected by incubation with
either E. faecium endocarditis patient serum (antibody I) or NHS obtained from
healthy volunteers, followed by horseradish peroxidase-conjugated goat anti-
human IgG antibodies (antibody II) and development with 4-chloronaphthol in
the presence of H2O2.
ELISAs using human sera and rAcm A protein were performed as previously
described (17). For ELISA, each serum was assayed in duplicate in serial dilu-
tions of 1:16 to 1:1,024 in 1% BSA. The sum of the average OD450 value and two
times the standard deviation for the pooled NHS was calculated for each dilution
and used as the cutoff value for determining serum titers.
PFGE. Agarose plugs containing genomic DNA were digested with SmaI or
ApaI, and pulsed-field gel electrophoresis (PFGE) was performed using a pre-
viously described method (15), but with ramped pulse times of 2 s and 30 s. Since
SmaI profiles were more discriminatory for some isolates and ApaI profiles were
more discriminatory for others, we used both for analysis. PFGE was performed
for all 17 endocarditis-derived E. faecium isolates (including 6 previously de-
scribed isolates) (20) and 6 collagen-adhering isolates from the Other-Clin group
with broad geographical and temporal diversity.
MLST. Multilocus sequence typing (MLST) and analysis of allelic profiles of
E. faecium isolates were performed as described previously (9), with the use of
primer sequences available at http://efaecium.mlst.net/misc/info.asp. Different
sequences of a given locus were assigned allele numbers, and different allelic
profiles were assigned sequence types (STs). MLST was carried out for one
isolate of the PF1 pulsotype, one of the PF2 pulsotype, and seven distinct
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pulsotype strains. Eight of these were derived from endocarditis samples, and
one was from the Other-Clin group (see Results for details on PF numbers).
Drug susceptibility testing. Vancomycin and ampicillin susceptibilities were
determined by agar dilution, with concentrations ranging from 4 to 64 g/ml;
MICs of 16 g/ml of ampicillin and 32 g/ml of vancomycin were considered
resistant, according to CLSI guidelines (4, 5).
Statistical analyses. Fisher’s exact test was used to determine the statistical
significance of the differences observed in collagen adherence phenotypes of
different strain groups. To determine if a correlation existed between collagen
adherence and Acm surface detection, Pearson’s correlation coefficient (r) was
calculated. One-tailed Student’s t test was used to compare Acm antibody levels
(at a 1:16 dilution) among the three groups of subjects.
RESULTS AND DISCUSSION
Association of clinical origin and collagen adherence in E.
faecium isolates from four continents. Since our previous pilot
survey (20) with 32 isolates suggested a relationship between in
vitro collagen adherence and clinical origin, we extended this
analysis to a diverse group of 90 additional E. faecium isolates
(including isolates of animal origin) from our collection. Eight
of 11 (73%) endocarditis-derived isolates and 18 of 31 (58%)
Other-Clin isolates showed in vitro adherence (defined as
5% of cells adhering [20]) to collagen type I (see Fig. 1,
which also shows data for the 30 nonlaboratory isolates previ-
ously reported [20]). All four catheter-derived infection iso-
lates (Other-Clin group) showed collagen adherence, and the
percentages of cells showing adherence among these strains
ranged from 10.2 to 54.5%. In contrast, only 1 of 25 commu-
nity-derived isolates from feces of healthy volunteers and 2 of
23 animal-derived isolates adhered to collagen, and this adher-
ence was at a low level, as shown in Fig. 1. A highly statistically
significant difference was observed between the percentages of
adherent strains in the endocarditis group and the community-
derived fecal isolate group or the animal isolate group (P 
0.0001 and P 0.0003, respectively; Fisher’s exact test), as well
as between the Other-Clin group and each of the nonclinical
groups (P  0.0001 and P  0.0002, respectively). Although
the percentage of in vitro collagen-adhering isolates was found
to be higher in the endocarditis group (73%) than in the
nonendocarditis Other-Clin group (58%), this difference was
not significant. The consistent association of clinical origin and
adherence, observed in two independent studies (here and in
our previous pilot survey [20]) with different isolates from four
continents, suggests that collagen adhesion may be a risk factor
that enhances the ability of E. faecium to survive, colonize,
and/or cause infection in the clinical setting.
Our further investigations in this study were designed to test
the hypotheses that (i) Acm is the primary collagen adhesin for
FIG. 2. Correlation between collagen adherence and surface dis-
play of Acm by 31 E. faecium strains (11 endocarditis isolates, 10
Other-Clin isolates, and 5 isolates from each of the nonclinical
groups). Adherence percentages were plotted as a function of OD450
values from a whole-cell ELISA using E. faecium strains and affinity-
purified anti-rAcm A-specific antibodies (P  0.0001 for correlation).
FIG. 1. Adherence of E. faecium isolates to immobilized collagen type I. Data points for 90 isolates in this study represent mean percentages
of cells adhering  standard deviations; data for 30 additional previously reported E. faecium nonlaboratory isolates (20) are shaded in gray.
Isolates were considered to adhere if 5% of total labeled cells adhered to collagen coating the well (34).
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isolates of diverse origins under the growth conditions tested;
(ii) the acm gene may be expressed during severe E. faecium
infections, such as endocarditis, even in isolates that do not
produce Acm in vitro; and (iii) a functional acm gene may
correlate with the increased occurrence of the hospital-associ-
ated E. faecium cluster of the distinct genogroup CC17.
The amount of surface Acm correlates with collagen adher-
ence. To investigate the correlation between Acm and collagen
type I adherence by diverse isolates, we assessed surface ex-
pression of Acm, using anti-Acm A domain affinity-purified
antibodies in a whole-cell ELISA. Thirty-one E. faecium iso-
lates, including 11 endocarditis isolates representing nine pulso-
types (see below), 10 Other-Clin isolates, and 5 isolates from
each of the nonclinical groups, were tested (Fig. 2). All of the
19 collagen-adhering strains were positive in this assay, and the
OD450 values of these strains ranged from 0.252 to 0.672 (Fig.
2), while the OD450 values for all 31 strains with preimmune
Igs ranged from 0.002 to 0.112 (data not shown). When the
collagen adherence percentages of the respective strains were
plotted as a function of the level (OD450) of surface-exposed
Acm, regression analysis showed that the amount of surface
Acm correlated strongly (r  0.879; P  0.0001) with the
degree of collagen adherence (Fig. 2).
To further test whether the observed variation in collagen
adherence of different isolates is due to variability in Acm
surface expression, we next quantified surface expression of all
five nonadhering and four adhering endocarditis isolates by
fluorescence-activated cell sorting analysis using Acm A-do-
main-specific antibodies and preimmune Igs. The binding of
anti-Acm to the surfaces of all four collagen-adhering strains
(TX0074, TX2535, TX0082, and TX2658) was readily detected
(Fig. 3A to D) and correlated well with the various levels of
collagen adherence observed in these strains. Furthermore,
anti-Acm did not exhibit any measurable binding to the sur-
faces of three nonadhering strains (TX0016, TX0080, and
TX6051 [TX0082 acm]) and bound to only a minor fraction
(4.1 to 6.6%) (Fig. 3E to J) of three other nonadhering strains
(TX0068, TX0110, and TX0111). Thus, our results indicate
FIG. 3. Quantitation of Acm surface expression by fluorescence-activated cell sorting analysis. (A to D) Analysis of four endocarditis-derived
collagen-adhering E. faecium isolates exhibiting different levels of collagen adherence. Percentages of radiolabeled cells adhering to collagen were
43%, 36%, 11%, and 6% for TX0074, TX2535, TX0082, and TX2658, respectively. (E to J) Analysis of five non-collagen-adhering E. faecium
endocarditis isolates and an acm deletion mutant of TX0082. Percentages of radiolabeled cells adhering to collagen were 2.3%, 2.7%, 3.9%, 2.3%,
and 2.2% for TX0016, TX0068, TX0080, TX0110, and TX0111, respectively. Bacteria were analyzed by flow cytometry, using side scatter as the
threshold for detection. Specific binding by anti-Acm antibodies is indicated as log fluorescence intensity on the x axis. Each histogram represents
50,000 events (bacterium-sized particles). PI, preimmune Igs; anti-Acm, anti-Acm A-domain-specific Igs.
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that the level of collagen adherence is related to the amount of
Acm on cell surfaces as well as to the percentage of cells
expressing Acm.
Taken together, these surface Acm results corroborate our
studies of acm constructs (18, 20), demonstrating that surface
localization of Acm is necessary and sufficient for collagen type
I adherence in clinical strains belonging to multiple pulsotypes
(see below) under the growth conditions used.
IS element-mediated disruptions of the acm gene are fre-
quent in isolates of nonclinical origin. Since a previous survey
of 56 E. faecium strains from Brazil showed the absence of acm
in one E. faecium isolate from a healthy human (2), we first
screened the isolates of this study for the presence of the acm
gene. Hybridization results showed that 89 of 90 (99%) E.
faecium isolates carried the acm gene, thus confirming its very
widespread nature; the exception was a purK allele 6 (non-
CC17) poultry isolate susceptible to both ampicillin and van-
comycin. Since this isolate served as a negative control for
surface expression studies, we have included it in the total n for
this study.
Because we previously found an acm pseudogene among
some nonadherent isolates, with interruptions by IS elements
(20), we next screened the 89 acm-positive isolates of this study
for acm interruption by PCR with overlapping primers cover-
ing the entire acm locus, followed by sequencing of selected
strains. The results showed interruption of acm (leading to a
pseudogene) in 0% of endocarditis isolates, 6% of Other-Clin
isolates, 24% of community fecal isolates, and 27% of animal
isolates and accounted for the nonadherence phenotype of
approximately one quarter of the nonclinical group isolates;
disruptions mapped to three regions and were caused by four
types of IS elements (Fig. 4). Although our earlier pilot study
(20) found that two of six nonadherent isolates had a mutation
leading to a premature stop codon, additional sequencing was
not performed, except for that of endocarditis isolates included
in our companion study (19).
Precise excision of IS256 from the acm pseudogene of clin-
ical strain TX2466 in the presence of collagen as a mechanism
for increased expression of Acm. Among two pseudogene-
containing Other-Clin isolates, one (TX2466), in which acm
was interrupted by IS256, was noted to show a faint band by
PCR that corresponded to the size of an uninterrupted acm
sequence, suggesting spontaneous excision of IS256 from acm.
After growth in collagen-supplemented (0.1 mg/ml) BHI
broth, this strain showed a slight increase in collagen adher-
ence (Fig. 5A). In addition, comparison of this strain by fluo-
rescence-activated cell sorting after passage of cells in collag-
en-coated wells versus passage in BHI showed an increase in
the percentage of cells (from 2.8% to 	16%) expressing Acm
on the surface (Fig. 5B). Subsequent testing of 
700 colonies
of TX2466 by PCR after repeated passages in wells coated with
immobilized collagen showed no completely revertant colo-
nies, although a higher-intensity, intact-size band was detect-
able in the mixture of cells after enrichment (Fig. 5C); se-
quencing of the eluted intact-size band identified precise
excision of the 1,332-bp IS256, including the initially dupli-
cated 8-bp target site (Fig. 5D). Whether “permanent” rever-
tant colonies could be obtained under different conditions re-
mains to be seen. Similar IS256-mediated modulation of
expression of a polysaccharide intercellular adhesin was previ-
ously demonstrated for staphylococci (35).
Anti-Acm antibodies are present in all patients with E. fae-
cium endocarditis, including those whose infecting isolates do
not express Acm in vitro. An indirect assessment of in vivo
FIG. 4. PCR detected acm disruptions in 14 different E. faecium isolates. (A) Schematic representation showing the positions of disruptions
by different IS elements analyzed in isolates of this study and a previous study (20). RBS, predicted ribosomal binding site; S, signal peptide; A
domain, nonrepetitive collagen binding domain; B domain, domain with variable number of repeats in different strains; W, cell wall domain with
motif required for sortase-mediated surface anchoring; M, membrane-spanning domain; and C, charged C-terminal domain. (B) Distribution of
disrupted acm genes among 89 acm-positive E. faecium isolates from this study. †, the four collagen-adherent and two nonadherent endocarditis
isolates of our previous study included in this study for molecular epidemiological analyses and surface expression level studies also had an
uninterrupted acm gene (20); *, a single isolate of animal origin lacked acm.
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expression is the demonstration of a serological response. We
initially screened five E. faecium endocarditis patient sera and
eight NHS from a healthy control group by Western blotting.
Among the five endocarditis sera, two reacted strongly and
three reacted moderately, suggesting that in vivo surface ex-
pression of Acm by different strains had occurred in these
patients (Fig. 6A); none of the sera from healthy controls
reacted with Acm. We then quantitatively assayed the presence
of Acm A-domain-specific antibodies from four different se-
rum groups, described in Materials and Methods. Strikingly, all
14 E. faecium endocarditis sera in our collection (including the
5 used in Western blot analyses) showed reactivity (Fig. 6B)
with rAcm A. Titers of the reactive E. faecium endocarditis
sera against rAcm A varied from 1:16 to 1:1,024. The endo-
carditis patient serum that showed the lowest titer (1:16) also
showed low titers against total enterococcal surface proteins
(data not shown). Of particular interest, among the five endo-
carditis isolates that did not show collagen adherence (includ-
ing two from a previous study [20]) (Fig. 1) or reaction with
anti-rAcm A antibodies in vitro (Fig. 3), sera were available
from four of the patients infected with these organisms. All
four patient sera had substantial antibodies to Acm (Fig. 6B,
black circles), despite our inability to demonstrate the pres-
ence of Acm or collagen adherence in vitro, supporting the
notion that Acm was expressed by these strains in vivo, even
though it was not expressed in vitro.
A total of 23 of 27 (85%) sera from E. faecium nonendocar-
ditis Other-Clin infections showed Acm antibody levels that
were greater than the control serum levels, and the remaining
4 sera from this group showed reactivity equal to that of con-
trols. Of the 15 nonhealthy control sera from hospitalized
patients, 12 reacted at levels that were the same or lower than
those of NHS and three had elevated anti-Acm antibody levels.
Clinical information was not obtained for these randomly cho-
sen nonhealthy control sera. Thus, we predicted that the three
positive patients may have had a prior E. faecium infection or
had cross-reacting antibodies. Likewise, 1 of 15 healthy control
group sera also had anti-Acm antibodies. A statistically signif-
icant difference was observed between the endocarditis group
and the nonendocarditis Other-Clin group versus each of the
control group sera (P  0.0003). Taken together, our results
suggest that Acm is produced during most E. faecium infec-
tions and promotes a host immune response.
The presence of a functional acm gene correlates with
increased occurrence of the hospital-associated E. faecium
genogroup CC17. To examine the possibility that the collagen
FIG. 5. IS256-mediated modulation of acm expression in E. faecium strain TX2466. (A) Enhanced collagen adherence of acm pseudogene-
containing E. faecium isolate TX2466 after growth in collagen-supplemented BHI broth. (B) Fluorescence-activated cell sorting analysis of TX2466
grown in BHI or grown in wells coated with collagen. PI, preimmune Igs; anti-Acm, anti-Acm A-domain-specific Igs. (C) Agarose gel electro-
phoresis of colony PCR amplification with primers AcmF1 and AcmR4, using a mixture of cells before and after repeated passages in wells coated
with immobilized collagen. (D) Schematic representation of the IS256 insertion site and its precise excision, confirmed by sequencing of the acm
gene of TX2466. The duplicated target sequences of IS256 transposase are boxed.
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adherence seen in isolates of clinical origin might represent
dissemination of closely related isolates, PFGE typing was
performed with a subset of isolates (see Materials and Meth-
ods). Among the 23 isolates analyzed, 8 isolates (6 endocarditis
isolates, 1 catheter isolate, and 1 wound isolate, isolated be-
tween 1988 and 2002 in several hospitals in Texas) were cate-
gorized as “closely related” or “possibly related” (3- or 3- to
6-band difference) (27) and were designated pulsotype PF1
(Fig. 7A). We also found another group (PF2) with two “pos-
sibly related” endocarditis isolates from Arizona and Texas
(Fig. 7A). In Fig. 7B, 12 individual strains showing consider-
able heterogeneity (7- to 11-fragment difference) in PFGE
fingerprints are shown, along with single representatives of
PF1 and PF2. It is interesting that the adherence percentages
of PF1 isolates also varied to a great extent, ranging from 6%
to 36%. Hybridization of PFGE Southern blots of chromo-
somal digestion fragments with an acm probe showed hybrid-
ization to the same-sized bands in all but one of the related
isolates and to 11 differently sized fragments in those that were
different by PFGE (data not shown). Taken together, our
PFGE analysis showed that collagen adherence was found in
at least 15 clearly different pulsotypes, thus demonstrating
that collagen adherence is not limited to closely related
isolates.
To evaluate more long-term evolutionary relationships, we
next used MLST (9) with a subset of distinct pulsotype isolates
(see Materials and Methods) and compared the results with an
international E. faecium MLST data set (available at www.mlst
FIG. 6. Reactivity of human serum with rAcm A protein. (A) Immunoblots of rAcm A protein probed with human sera. Lanes 1, 2, and 4 to
6, sera from different patients with E. faecium endocarditis; lane 3, molecular size standards; lanes 7 to 14, NHS obtained from healthy volunteers.
(B) Distribution of anti-Acm A domain Ig titers in human sera. The four endocarditis patient sera that had antibodies to Acm but whose infecting
strain lacked in vitro collagen adherence and surface Acm are shaded in black. Sera from hospitalized patients as well as healthy volunteers were
used as two groups of controls.
FIG. 7. Analysis of 23 E. faecium isolates by PFGE. (A) SmaI PFGE profiles of PF1, PF2, and other strains. Six endocarditis, one catheter, and
one wound isolate, isolated between 1992 and 2002 from several hospitals in Texas, were categorized as PF1. Two endocarditis isolates from
Arizona and Texas were categorized as possibly related (PF2). (B) SmaI PFGE profiles of strains with distinct PFGE patterns. Nonendocarditis
isolates belonging to the Other-Clin group are marked with the symbol “§”.
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.net); the results showed that eight of the nine isolates typed
are ancestrally related. As shown in Table 1, the STs obtained
were ST17 (n  4), ST18 (n  2), ST16 (n  1), ST154 (n 
1), and ST337 (n  1); of these, the first four STs, which are
single-locus variants of each other, represent 16 isolates (based
on the PFGE results) and are part of the distinct nosocomial
high-risk CC17 genogroup, which has a global distribution (11,
32). High genome plasticity observed in CC17 strains due to
their having significantly more mobile elements in their
genomes (12) could explain the evolution of the chromosomes
of these CC17-linked clinical strains, thus leading to the
distinct PFGE patterns observed here.
Since the purK allele used in MLST has been defined as an
epidemic marker of CC17 lineage (31), we also characterized
the purK alleles of the remaining 9 endocarditis isolates, 16 (8
collagen-adhering and 8 nonadhering isolates) isolates from
the Other-Clin group, and 8 isolates from each nonclinical
group. Twenty-three of 25 clinical isolates contained purK1
(characteristic of the hospital-associated CC17 lineage, but
found infrequently in other STs), while the remaining two
contained purK2 and purK6. Although purK2 and purK6 differ
from purK1 by 1 and 2 nucleotides, respectively, these alleles
are frequently encountered in nonclinical isolates (9). The
nonclinical group isolates had a diverse group of purK alleles,
including purK2 (n  2), purK3 (n  2), purK6 (n  5), purK8
(n  4), purK9 (n  1), purK17 (n  1), and purK22 (n  1).
The overall combined results of PFGE, MLST, and purK
allele analyses implicated 39 of 42 clinical isolates and 0 of 16
nonclinical isolates as being CC17 related. Another striking
observation was that among the 17 endocarditis isolates ob-
tained from various geographical locations in the United States
from 1992 to 2002, all but 1 belongs to the CC17 genogroup.
Testing for vancomycin and ampicillin resistance showed a
very strong association between ampicillin resistance, clinical
origin, and collagen adherence (Table 2); however, vancomy-
cin resistance (predominantly vanA) was found in both clinical
(74%) and animal (48%) isolate groups. All vancomycin-resis-
tant animal isolates were from Europe. Although the presence
of esp and of hyl was independently associated with clinical
origin, as anticipated from previous reports (11, 23), these
genes were each present in only 41% of endocarditis isolates
and 36 to 71% of Other-Clin group isolates (Table 2). These
data support the previously proposed hypothesis of acquisition
of ampicillin resistance and then vancomycin resistance, as well
as activation (e.g., acm) or acquisition (e.g., esp or hyl) of other
genetic traits to facilitate infection, colonization, and/or trans-
mission, although the order of these events cannot currently be
determined (11, 23, 31).
In summary, analysis of E. faecium strains of multiple pulso-
types showed a collagen adherence phenotype in 62% of clin-
ical versus 6% of nonclinical isolates. In vitro production of
Acm was found to be very highly correlated with a collagen
adherence phenotype, supporting the concept that Acm is the
primary collagen adhesin of E. faecium in vitro. Our results
also demonstrate that the amount of Acm detected on bacte-
rial cell surfaces is the primary determinant of the observed
variation in collagen adherence of individual strains. Impor-
TABLE 2. Frequencies of ampicillin and glycopeptide resistance as
well as esp and hyl genes among E. faecium strains
of diverse origins
Epidemiologic source (n)
No. of isolates
resistant to:
No. of
isolates
with
gene
Ampicillin Vancomycin(vanA, vanB) esp hyl
Endocarditis patients (17)a 17 12 (10, 2) 7 7
Collagen adherent (12) 12 9 (7, 2) 3 4
Nonadherent (5) 5 3 (3, 0) 4 3
Other-Clin isolates (31) 28 24 (17, 7) 20 10
Collagen adherent (18) 18 16 (11, 5) 12 4
Nonadherent (13) 10 8 (6, 2) 8 6
Community fecal isolates (25) 0 3 (3, 0) 0 0
Collagen adherent (1) 0 0 0 0
Nonadherent (24) 0 3 (3, 0) 0 0
Animal isolates (23) 2 11 (11, 0) 0 0
Collagen adherent (2) 0 2 (2, 0) 0 0
Nonadherent (21) 2 9 (9, 0) 0 0
a Includes six isolates from our previous study (20), including four collagen-
adherent and two nonadherent strains.
TABLE 1. Ancestral relatedness of a subset of E. faecium isolates exhibiting distinct pulsotypes
Strain Clinical source; origin; yr of isolation/collection Ampicillin/vancomycinMICs (g/ml)a
Presence of
esp/hylb PFGE type
c
MLST type (allelic profiles
for atpA, ddl, gdh, purK,
gyd, pstS, and adk)
TX2400 Blood; Galveston, TX; 1994 	64/	64 / PF9 ST16 (1, 2, 1, 1, 1, 1, 1)
TX0067d Endocarditis/blood; Houston, TX; 1994 	64/4 / PF4 ST17 (1, 1, 1, 1, 1, 1, 1)
TX0082d Endocarditis/blood; Houston, TX; 1999 64/	64 / PF1 ST17 (1, 1, 1, 1, 1, 1, 1)
TX0110d Endocarditis/blood; Houston, TX; 2002 	64/	64 / PF2 ST17 (1, 1, 1, 1, 1, 1, 1)
TX0080 Endocarditis/blood; Worcester, MA; 1996 	64/	64 / PF7 ST17 (1, 1, 1, 1, 1, 1, 1)
TX0016e Endocarditis/blood; Houston, TX; 1992 16/4 / PF3 ST18 (7, 1, 1, 1, 5, 1, 1)
TX0068 Endocarditis/blood; Worcester, MA; 1994 64/4 / PF5 ST18 (7, 1, 1, 1, 5, 1, 1)
TX0081 Endocarditis/blood; Baltimore, MD; 1996 	64/	64 / PF8 ST154 (9, 2, 1, 1, 1, 1, 1)
TX0074 Endocarditis/blood; Valhalla, NY; 1995 64/	64 / PF6 ST337f (5, 3, 1, 38, 8, 6, 1)
a MICs of 16 g/ml for ampicillin and 32 g/ml for vancomycin are considered to indicate resistance.
b , gene present; , gene absent.
c A distinct PFGE type was defined as differing by more than six fragments from other types.
d Isolates were from the same hospital.
e Designated DO in previous studies (20).
f Non-CC17 isolate.
VOL. 76, 2008 CONTRIBUTION OF Acm TO E. FAECIUM CLINICAL SUCCESS 4117
tantly, the presence of antibodies to Acm in all 14 endocarditis
patient sera and 85% of sera from other E. faecium infections
tested provides evidence of Acm production in vivo during
serious infections. Among the 17 endocarditis isolates, we
found Acm production in vitro with 12 isolates and indirect
evidence of Acm production in vivo during endocarditis with
an additional 4 isolates. The extent of surface display of Acm
and its highly conserved nature (19), along with our recent data
showing that antibodies against Acm subsegments inhibit col-
lagen adherence of E. faecium (16), underscore the possibility
of using Acm as a target for immunoprophylaxis or in combi-
nation with antibiotics (29). Finally, while antibiotic resistance
certainly contributes to the difficulty in managing E. faecium
infections, its contribution to the increase in frequency of this
organism in nosocomial infections remains less certain. In-
deed, vancomycin resistance is not uncommon in strains of
non-CC17 origin in animals and in commensal strains from
healthy humans in Europe, which very rarely, if ever, cause
infection. In conclusion, the results from our molecular epide-
miological analyses, together with the data from our compan-
ion paper demonstrating Acm’s role in E. faecium endocarditis
(19), suggest that a functional acm gene, a predictor of colla-
gen adherence, helps to explain the increased virulence poten-
tial of the CC17 epidemic genogroup.
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